SciSparc Ltd. (Nasdaq: SPRC) announced that its subsidiary NeuroThera Labs Inc. has demonstrated a complete end-to-end hybrid quantum-classical workflow for clinical trial data analytics, according to a press release dated July 31, 2026.

The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes. It covers the full analytical pipeline, from data ingestion and preparation through quantum-enabled processing to the generation of clinically interpretable insights.

The platform is described as capable of supporting quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical datasets. The company states the milestone confirms the platform can handle complex, high-dimensional biomedical datasets using quantum-inspired methodologies.

The platform is being developed through CliniQuantum Ltd., a quantum-focused technology initiative in which NeuroThera holds a 54.01% interest. Planned next steps include expanding the scale of supported datasets, optimizing quantum algorithms, and conducting performance studies evaluating the potential contribution of quantum computing to clinical research and precision medicine applications.

SciSparc, through NeuroThera, is also engaged in cannabinoid-based drug development programs targeting Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus.